Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma

rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Inclusion Criteria:

• Untreated mantle cell lymphoma

Exclusion Criteria:

• Pregnant or breast feeding